The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

Leukemia

Volumn 29, Issue 2, 2015, Pages 464-473

  Robinson, S ^a   Dreger, P ^b   Caballero, D ^c   Corradini, P ^d   Geisler, C ^e   Ghielmini, M ^f   Le Gouill, S ^g   Kimby, E ^h   Rule, S ⁱ   Vitolo, U ^j   Dreyling, M ^k   Hermine, O ^l  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e Rigshospitalet   (Denmark)

^f ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ DERRIFORD HOSPITAL   (United Kingdom)

^j CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^k UNIVERSITY OF MUNICH   (Germany)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; RITUXIMAB; MONOCLONAL ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONSENSUS; DRUG MEGADOSE; HUMAN; LOW RISK PATIENT; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TELECONFERENCE; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CONSENSUS DEVELOPMENT; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; PROCEDURES; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CYTARABINE; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84922433879     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.223     Document Type: Article

References (61)

1. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518.
2. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
3. Geisler C, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo -purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
4. Olivier Hermine Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.
5. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzneret B et al. Immunochemotherapy with Rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
6. Rule S, Smith P, Johnson PW, Bolam S, Follows GA, Gambell J et al. The addition of Rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the Randomised UK National Cancer Research Institute (NCRI) Trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 440.
7. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Proet B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with Rituximab plus hyper-CVAD alternating with Rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
8. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
9. Geisler C, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive firstline immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530-1533.
10. 18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8: 159-165.
11. Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1693-1701.
12. Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Linet D et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010; 21: 133-139.
13. Determann O, Hoster E, Ott G, Bernd HW, Loddenkemper C, Hansmann ML et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385-2387.
14. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
15. Fernandez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
16. Nygren L, Wennerholm SB, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119: 4215-4223.
17. Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
18. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793-800.
19. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144-4152.
20. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535-3542.
21. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
22. Robinson S, Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz de Elvira C et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100 : 4310-4316.
23. Cook G, Smith G, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. BBMT 2010; 16: 1419-1427.
24. Fenske TS, Zhang M-J, Carreras J, Ayala E, Burns LJ, Cashen A et al. Autologous or reduced intensity allogeneic hematopoietic stem cell transplantation for chemotherapy-sensitive mantle cell lymphoma: Analysis of transplantation timing and modality. J Clin Oncol 2014; 32: 273-281.
25. Loblaw AD, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136-3140.
26. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, López-Guillermo A et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013; 98: 1014-1021.
27. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166-171.
28. Artz AS. From biology to clinical practice: aging and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18(Suppl): S40-S45.
29. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and co-morbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954-964.
30. Muffly LS, Boulukos M, Swanson K, Kocherginsky M, del Cerro P, Schroeder L et al. Pilot study of Comprehensive Geriatric Assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant 2013;19: 429-434.
31. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323.
32. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
33. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012; 119: 4939-4948.
34. Budhe LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM et al. Mantle Cell Lymphoma International Prognostic Index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving highdose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023-3029.
35. McKay P, Leach M, Jackson R, Cook G, Rule S. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012; 159: 405-426.
36. Dreyling M. How I treat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
37. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus Conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877.
38. Caballero D, Campo E, Lopez-Guillermo A, Martin A, Arranz-Saez R, Gine E et al. Clinical practice guidelines for diagnosis, treatment and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Ann Hematol 2013; 9: 1151-1179.
39. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: 6-year follow up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stemcell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
40. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101-6108.
41. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208.
42. Kahl B, Patel M, Younes A, Horwitz S, Foss FM, Oki Y et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ, γ in patients with relapsed/refractory B-cell lymphoma. Hematol Oncol 2013; 31 (Suppl 1): abstract 66.
43. Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275-1276.
44. 18 F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 2011; 52: 1898-1902.
45. Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2012; 118: 3565-3570.
46. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271-2278.
47. Rubio MT, Boumendil A, Luan JJ, Canals C, Lefrere F, Attal M et al. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the lymphoma working party of the EBMT. Blood 2010; 116: 688.
48. Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Tarella C. High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. BMT 2009; 43: 509-511.
49. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to Rituximab plus chemotherapy (PRIMA): A phase 3, randomized controlled trial. Lancet 2011; 377: 42-51.
50. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzneret W et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2013; 31: 1624-1630.
51. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H et al. Maintenance therapy with Rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
52. Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J et al. Maintenance Rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17: 1418-1423.
53. Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W et al. Maintenance Rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymp 2011; 52: 1675-1678.
54. Dietrich S, Weidle J, Rieger M, Meissner J, Radujkovic A, Ho AD et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia 2013; 28: 708-709.
55. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Feyet MF et al. Effect of single-agent Rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705-711.
56. Le Gouill S, Callanan M, Macintyre E, Delfau-Larue MH, Bodet-Milin C, Meignan M et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa Trial, a Lysa study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 152.
57. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270-1276.
58. Dietrich S, Finel H, Boumendil A, Avivi I, Volin L, Cornelissen J et al. Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the EBMT. Blood (ASH Annual Meeting Abstracts) 2012; 120: 474.
59. Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859-863.
60. Ringden O, Labopin M, Frassoni F, Sanz GF, Demeocq F, Prentice HG et al. Allogeneic bone marrow transplant or second autograft in patients who relapse after an autograft. Bone Marrow Transplant. 1999; 24: 389-396.
61. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.